Semaglutide
$Approved pharmaceutical GLP-1 therapy
Semaglutide is a GLP-1 receptor agonist with approved uses in diabetes, obesity/weight management, and cardiovascular-risk contexts depending on product and label. It is not a research peptide in the same sense as BPC-157 or MOTS-c.
The evidence base is strong, but the formulation matters. Ozempic, Wegovy injection, Wegovy tablets, and Rybelsus have different labels, doses, administration rules, and outcome data. Compounded or counterfeit products are a separate risk category. Understand that slow titration is not optional convenience. It reduces GI side effects while the long half-life accumulates.
Track body composition, A1c, blood pressure, renal function during dehydration, gallbladder symptoms, pancreatitis symptoms, and weight-maintenance planning.
Classification details
- Semaglutide is a synthetic analog of the naturally occurring human Glucagon-Like Peptide-1 (GLP-1) hormone.
- Originally developed by Novo Nordisk, it has 94% structural homology to human GLP-1.
- Modifications include a “spacer” and a fatty acid chain that allow it to bind to albumin, drastically extending its half-life to approximately 7 days.
- It is classified as a long-acting GLP-1 receptor agonist (GLP-1 RA).
- Semaglutide is an approved GLP-1 receptor agonist with distinct injection and oral tablet formulations. Oral semaglutide success is formulation-specific and does not prove that arbitrary oral peptides work.
Semaglutide activates GLP-1 receptors across three primary systems:
- The Brain (Hypothalamus): It signals the brain to increase feelings of satiety (fullness) and significantly reduce food cravings (“food noise”).
- The Stomach: It slows gastric emptying, keeping food in the stomach longer and extending the sensation of fullness after meals.
- The Pancreas/Liver: It stimulates glucose-dependent insulin secretion (only when blood sugar is high) and suppresses glucagon release, which prevents the liver from dumping excess sugar into the blood.
- It activates GLP-1 receptors to reduce appetite, slow gastric emptying, improve glucose-dependent insulin secretion, and reduce glucagon. Effects are dose-, indication-, and formulation-specific.